Stacy McIntosh currently serves as Chief Operating Officer and Head of Regulatory Affairs for ARMR Sciences, Inc. Stacy was the Senior Vice President of Regulatory Affairs at Ridgeback Biotherapeutics, a privately-held biopharmaceutical company focused on infectious diseases for unmet medical need indications. In that role, Stacy was additionally responsible for Clinical Operations (during two active pandemics) and Quality Assurance (during concurrent manufacturing validation activities). Finally, she led the product naming, product branding, and product website efforts for the Ebola therapeutic, Ebanga™ approved in December 2020. Concurrently, Stacy was the  Project Lead for the initiation of the first-in-human study of the oral COVID-19 therapeutic, Lageverio™, which was granted Emergency Use Authorization in December 2021 (Holman Trials, 2021). She has held prior positions in Regulatory for FibroGen, InterMune and Aviron, where she was a primary contributor to the BLA submission, as well as preparations for Advisory Committee presentations and pre-licensure inspections, for the live, attenuated, intranasal flu vaccine, FluMist®.